secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENEREX PHARMA, INC. (RGPX)
CIK:        0001357878
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001472375-23-000134
Event type: other
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans
--------------------------------------------------------------------------------

- Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.
- Claims 95% of chronic wounds show 100% closure within 90 days in clinical evaluations.
- Manufacturing to begin in Q4 2023 at facility in Memphis, TN.
- No specific management officer or director names were provided in the update.
- Products are FDA-cleared or OTC; Accelerex is a prescription-only combination device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/0001472375-23-000134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/ixform8k.htm
  HTML page:      https://secwatch.observer/filing/0001472375-23-000134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer